Nanoparticle vaccine fights respiratory syncytial virus
Inventors at the University of Iowa have developed a respiratory syncytial virus vaccine. It is a nanovaccine consisting of viral proteins encapsulated by biodegradable polyanhydride polymers.
Respiratory syncytial virus (RSV) is the leading cause of serious lower respiratory infection in children worldwide, and causes an estimated 160,000 deaths each year. The virus also affects adults, particularly those with compromised immune systems or suffering from heart or lung disease.
The nanovaccine includes the stabilized prefusion F protein, which allows for better exposure of the major RSV antigenic site, and the M protein, which contains epitopes that are targeted by both CD4 and CD8 T cells. Encapsulation with the inventor’s newly developed nanoparticle allows for continual, controlled release of the antigen resulting in robust T and B cell responses.
- US Patent Application No. 16/666,214
- Steven Varga, Department of Microbiology and Immunology